FDA accelerated Rocket Pharma recently secured FDA accelerated approval for KRESLADI gene therapy in pediatric severe LAD-I, presenting a potential opportunity to expand access programs, payer discussions, and companion diagnostics or monitoring services to support rapid patient uptake.

Rare Disease Voucher The company obtained a Rare Pediatric Disease Priority Review Voucher, creating a potential pathway for partnerships around regulatory strategy, expedited trials, and monetization opportunities that could be coupled with collaboration on commercialization services.

ATMO/Capable With an active at-the-market program through Cantor Fitzgerald & Co., there is a channel for incremental equity funding tied to pipeline milestones, which could be complemented by strategic advisory, market access planning, and stakeholder Communications services.

Pipeline focus Recent headcount reductions and pipeline narrowing suggest a focus on late-stage or near-term assets; sales discussions can target support for late-stage manufacturing, process development, and scale-up services, as well as risk-and-compliance documentation for regulatory filings.

Competitive landscape Given litigation history and ongoing competition in gene therapies, there is a need for robust IP due diligence, strategic partnerships, and clinical trial operations support to differentiate with data integrity, safety monitoring, and partner ecosystem services.